Floatz logo

Samuraciclib

Mucinous Adenocarcinoma

University Health Network, TorontoSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Mucinous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Stony Brook University
Phase 3BB
Carboplatin
National Cancer Institute (NCI)
Phase 3B
Docetaxel
National Cancer Institute (NCI)
Phase 3B
Eloxatin
University Hospital, Akershus
Phase 2CCC
Nivolumab
University Hospital, Akershus
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Samuraciclib is also rated in:

breast cancerDormant
B
Indicative ·
61 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced Solid MalignanciesDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →